Canada Moves To Boost Biosimilar Market
Biosimilar uptake in Canada is expected to benefit from moves to switch patients onto biosimilars and the removal of health technology appraisal reviews from the process for listing drugs on public plans.
Biosimilar uptake in Canada is expected to benefit from moves to switch patients onto biosimilars and the removal of health technology appraisal reviews from the process for listing drugs on public plans.